Clinical Trials: Page 103
-
ASCO17: Juno marks progress with second-gen CAR-T
Updated results for JCAR017 looked competitive in lymphoma as Juno hopes to recover from its earlier safety setbacks with its now shuttered JCAR015 program.
By Ned Pagliarulo • June 5, 2017 -
Montgomery County Planning Commission
ASCO17: Merck touts Keytruda bladder benefit post Tecentriq failure
Data announced for Keytruda in bladder cancer raises questions about the differences in checkpoint inhibitors after Roche's recent failure in the space.
By Suzanne Elvidge • June 5, 2017 -
Explore the Trendline➔
Getty Images
TrendlineNeuroscience drug development
Enthusiasm is running higher among drugmakers and investors for neuroscience drug development, buoyed by recent approvals of new Alzheimer’s, ALS and depression medicines.
By BioPharma Dive staff -
ASCO17: J&J seeks label expansion for Zytiga
The pharma's prostate cancer drug was a big winner at ASCO, with data showing a 38% reduction in the chance of death for high-risk patients when adding Zytiga to standard hormonal therapy.
By Jacob Bell • June 5, 2017 -
ASCO17: Roche's Perjeta cuts risk in Aphinity, but is it enough?
The large Phase 3 study has been closely watched as potentially practice-changing, but the modest benefit could limit its impact somewhat in adjuvant treatment of breast cancer.
By Ned Pagliarulo • June 5, 2017 -
ASCO17: Roche's Alecensa bests Xalkori in lung study
The ALK inhibitor from the Swiss pharma dramatically improved progression-free survival over Xalkori, potentially positioning itself as the new standard of care.
By Ned Pagliarulo • June 5, 2017 -
ASCO17: AstraZeneca's Lynparza stays step ahead of PARP rivals
Data showing a 42% risk reduction in disease worsening compared to chemo in breast cancer patients should help build Lynparza's profile outside of ovarian cancer.
By Ned Pagliarulo • June 4, 2017 -
ASCO17: Incyte pads its IDO numbers
IDO inhibitors have been pegged as the next step in immuno-oncology combinations, but Incyte's rising market value prompts questions over what that's worth.
By Ned Pagliarulo • June 3, 2017 -
ASCO17: Loxo shows promise of biomarker approach to cancer
Clinical data presented Saturday showed treatment with Loxo Oncology's larotrectinib shrank tumors in three-quarters of patients with a range of 17 different advanced cancers.
By Ned Pagliarulo • June 3, 2017 -
Prescribed Reading: Combos to take center stage at ASCO
On the eve of ASCO, some question the validity of certain combination testing for oncology drugs, pointing to the increased number of combo trials taking place.
By Lisa LaMotta • June 2, 2017 -
Opinion
The perils of building clinical trials on a shaky foundation
With the odds stacked against clinical trial success, drug developers need all the tools in their arsenal to make sure they recruit patients quickly and design trials effectively.
By Craig Morgan • June 1, 2017 -
Sponsored by inVentiv Health
Critical considerations for successful immunotherapy trials
Every cancer immunotherapy trial is different, but there are several best practices biopharmaceutical companies can follow to shorten the distance from lab to life.
June 1, 2017 -
Phase 3 success keeps Teva in migraine race
No headache for Teva as it announces positive trial results for its migraine drug, one of several new treatments nearing potential approval.
By Suzanne Elvidge • June 1, 2017 -
Lilly's Cyramza scores in bladder cancer
The positive data could set the company up to compete with a range of checkpoint inhibitors in the indication.
By Lisa LaMotta • May 31, 2017 -
NLS touts Mazindol's efficacy as it takes on ADHD market
The clinical-stage pharma revealed that the majority of patients taking its ADHD drug in a Phase 2 trial had at least a 50% reduction in disease symptoms.
By Jacob Bell • May 31, 2017 -
Gilead tees up filing for HIV triple combo after Phase 3 wins
The biotech hopes the therapy, if approved, will accelerate the adoption of its portfolio of newer HIV treatments, which have become more important as HCV sales fall fast.
By Ned Pagliarulo • May 30, 2017 -
Sponsored by Covance
Finding the other 90%: Attracting naïve patients to RA studies
There is significant research being targeted towards the treatment of rheumatoid arthritis (RA), but how can the industry attract more clinical trial participants?
May 30, 2017 -
Novo Nordisk seeks expanded label for Tresiba
The DEVOTE study showed non-inferiority in cardiovascular safety and improvement in hypoglycemia — but will this be enough for the FDA?
By Suzanne Elvidge • May 30, 2017 -
Deep Dive
Industry Pulse: R&D spending in charts
Biopharmas are always on the hunt for ever-elusive innovations, but some are better at allocating investment than others. Here are five charts showing how the industry spends on R&D.
By Ned Pagliarulo • May 30, 2017 -
Prescribed Reading: FDA on a roll, while pharma continues sell off
The regulatory agency continues its approval spree, just as big pharma sells off older assets in its ongoing restructuring.
By Lisa LaMotta • May 26, 2017 -
Hopes are high for cannabinoid data in epilepsy
GW Pharmaceuticals' stock price spiked after it published epilepsy data, and submission for Epidiolex in the U.S. is now imminent.
By Suzanne Elvidge • May 26, 2017 -
Aerie shares rise on trial success for eye drug
The positive results could help Aerie make the jump from a clinical-stage company to a commercial one over the next two years.
By Ned Pagliarulo • May 25, 2017 -
Neurocrine's Tourette's trial gets a red light
Ingrezza failed to beat placebo in a Phase 2 trial, pushing its stock price down.
By Suzanne Elvidge • May 24, 2017 -
Trial success buoys AstraZeneca's hopes for asthma biologic
Benralizumab is the most advanced example of AstraZeneca's push to expand its respiratory portfolio into biologics.
By Ned Pagliarulo • May 23, 2017 -
Celgene MS drug succeeds in second Phase 3 study
But the drug failed to beat out Biogen's Avonex in slowing disability progression, a missed opportunity to stand out in a crowded therapeutic class.
By Ned Pagliarulo • May 22, 2017 -
La Jolla falls on mixed results for shock treatment
The drug met its primary endpoint, boding well for its chances with the FDA. But results were less promising on secondary measures of organ failure and mortality.
By Suzanne Elvidge • May 22, 2017
Previous
